CN104619334A - 超级因子和合成因子:具有新的和增强的信号传导活性的经改造细胞因子 - Google Patents

超级因子和合成因子:具有新的和增强的信号传导活性的经改造细胞因子 Download PDF

Info

Publication number
CN104619334A
CN104619334A CN201380047839.4A CN201380047839A CN104619334A CN 104619334 A CN104619334 A CN 104619334A CN 201380047839 A CN201380047839 A CN 201380047839A CN 104619334 A CN104619334 A CN 104619334A
Authority
CN
China
Prior art keywords
receptor
cytokine
mutein
cells
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380047839.4A
Other languages
English (en)
Chinese (zh)
Inventor
C·K·加西亚
D·L·巴特斯
I·莫拉加
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Priority to CN201910717548.0A priority Critical patent/CN110615835A/zh
Publication of CN104619334A publication Critical patent/CN104619334A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201380047839.4A 2012-08-09 2013-08-08 超级因子和合成因子:具有新的和增强的信号传导活性的经改造细胞因子 Pending CN104619334A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910717548.0A CN110615835A (zh) 2012-08-09 2013-08-08 选择性地操纵靶细胞中对两个或更多个共有受体多肽识别的配体的细胞反应的方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261681490P 2012-08-09 2012-08-09
US61/681490 2012-08-09
US201261725791P 2012-11-13 2012-11-13
US61/725791 2012-11-13
US201361825980P 2013-05-21 2013-05-21
US61/825980 2013-05-21
PCT/US2013/054164 WO2014074186A2 (en) 2012-08-09 2013-08-08 Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910717548.0A Division CN110615835A (zh) 2012-08-09 2013-08-08 选择性地操纵靶细胞中对两个或更多个共有受体多肽识别的配体的细胞反应的方法

Publications (1)

Publication Number Publication Date
CN104619334A true CN104619334A (zh) 2015-05-13

Family

ID=50685291

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380047839.4A Pending CN104619334A (zh) 2012-08-09 2013-08-08 超级因子和合成因子:具有新的和增强的信号传导活性的经改造细胞因子
CN201910717548.0A Pending CN110615835A (zh) 2012-08-09 2013-08-08 选择性地操纵靶细胞中对两个或更多个共有受体多肽识别的配体的细胞反应的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910717548.0A Pending CN110615835A (zh) 2012-08-09 2013-08-08 选择性地操纵靶细胞中对两个或更多个共有受体多肽识别的配体的细胞反应的方法

Country Status (6)

Country Link
US (3) US9738696B2 (cg-RX-API-DMAC7.html)
EP (1) EP2882449B1 (cg-RX-API-DMAC7.html)
JP (2) JP6445434B2 (cg-RX-API-DMAC7.html)
CN (2) CN104619334A (cg-RX-API-DMAC7.html)
IN (1) IN2015KN00329A (cg-RX-API-DMAC7.html)
WO (1) WO2014074186A2 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110582293A (zh) * 2017-03-31 2019-12-17 小利兰·斯坦福大学托管委员会 合成因子组合物及使用方法
US12540188B2 (en) 2020-08-05 2026-02-03 Synthekine, Inc. IL10Rα/IL2Rγ synthetic cytokines

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11198717B2 (en) * 2016-09-30 2021-12-14 The Board Of Trustees Of The Leland Stanford Junior University Variant type III interferons and synthekines
JP2018157812A (ja) * 2017-03-23 2018-10-11 東ソー株式会社 試料中に含まれる細胞の検出方法
MX2020012251A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
US20210130430A1 (en) 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
WO2019232523A1 (en) 2018-06-01 2019-12-05 The Board Of Trustees Of The Leland Stanford Junior University Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
JP7641912B2 (ja) 2019-04-19 2025-03-07 シナーキン・ファーマ・ベスローテン・フエンノートシャップ Ｉｌ１３を含む融合タンパク質
BR112021022666A2 (pt) 2019-05-14 2022-03-29 Werewolf Therapeutics Inc Frações de separação e seus métodos e uso
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
MX2022008770A (es) 2020-01-14 2022-10-07 Synthekine Inc Muteinas de la il2.
EP4532018A4 (en) * 2022-05-24 2026-04-22 Univ Pittsburgh Commonwealth Sys Higher Education EYE COMPOUNDS BASED ON INTERLEUKIN 4 AND/OR INTERLEUKIN 13

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335426B1 (en) * 1996-06-14 2002-01-01 Bayer Corporation T-cell selective interleukin-4 agonists

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0656947A1 (en) 1992-08-21 1995-06-14 Schering Corporation Human interleukin-13
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
FR2742156A1 (fr) 1995-12-06 1997-06-13 Sanofi Sa Polypeptide recepteur de l'il-13
US6028176A (en) * 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
US6673602B1 (en) 1999-06-11 2004-01-06 The General Hospital Corporation Herpes simplex virus amplicon vector targeting system and method of using same
US6737511B1 (en) 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
DE60038304T3 (de) 1999-09-09 2017-04-06 Merck Sharp & Dohme Corp. Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen
JP2003511019A (ja) 1999-10-06 2003-03-25 ザ ペン ステート リサーチ ファウンデーション Ｉｌ１３変異体
WO2001034645A2 (en) 1999-11-11 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Mutated il-13 molecules and their uses
GB0004016D0 (en) 2000-02-22 2000-04-12 Royal Brompton Hospital Biological material and uses thereof
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
JP4863150B2 (ja) 2000-08-30 2012-01-25 ザ・ペン・ステート・リサーチ・ファンデーション インターロイキン１３のアミノ酸置換変異体
WO2002032406A2 (en) 2000-10-18 2002-04-25 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
US7087224B2 (en) 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
IL159215A0 (en) 2001-06-07 2004-06-01 Wyeth Corp A solution of interleukin-13 and methods utilizing the same
US20040248260A1 (en) 2001-10-26 2004-12-09 Heavner George A. IL-13 mutein proteins, antibodies, compositions, methods and uses
US20060263368A1 (en) 2005-01-10 2006-11-23 Research Development Foundation Targeted chimeric molecules for cancer therapy
WO2008039173A2 (en) 2005-09-09 2008-04-03 Government Of The United States Of Amercica, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for inhibiting cell death or enhancing cell proliferation
WO2007048019A2 (en) 2005-10-20 2007-04-26 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
HUE044182T2 (hu) 2006-06-07 2019-10-28 Genzyme Corp Génterápia amiotrófiás laterális szklerózis és más gerincvelõ-rendellenességek kezelésére
WO2008101671A2 (en) 2007-02-19 2008-08-28 Apogenix Gmbh Il-4 fc fusion proteins
US9155798B2 (en) 2007-08-24 2015-10-13 Regents Of The University Of Minnesota Receptor-targeting reagents containing epidermal factor receptor-binding agents and IL-13 receptor-binding agents or IL-4 receptor-binding agents
US20110077202A1 (en) 2008-05-16 2011-03-31 Bayer Healthcare Llc Targeted Coagulation Factors and Method of Using the Same
WO2010031185A1 (en) 2008-09-19 2010-03-25 Protox Therapeutics Inc. Treating cancer stem cells using targeted cargo proteins
US20100183545A1 (en) 2008-10-14 2010-07-22 The United States Of America, As Represented By The Secretary, Targeted cargo protein combination therapy
JP2010154842A (ja) 2008-12-03 2010-07-15 Koji Kawakami Ｅｇｆｒを標的にした新規抗がんキメラペプチド
US20110023680A1 (en) 2009-07-30 2011-02-03 Kuo-Chung Wang Pcb cutter module with detachable cutters
TWI397428B (zh) 2009-12-29 2013-06-01 財團法人工業技術研究院 標的第四介白素受體之傳輸系統
WO2011106779A1 (en) * 2010-02-26 2011-09-01 Aerovance Inc. Use of modified il-4 mutien receptor antagonists to treat dermatitis
US9076405B2 (en) 2010-03-03 2015-07-07 Sharp Kabushiki Kaisha Display device, method for driving same, and liquid crystal display device
US20160354472A1 (en) 2010-10-22 2016-12-08 Protox Therapeutics Corp. Use of human serum albumin to decrease antigenicity of therapeutic proteins
WO2012088446A1 (en) 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
WO2012139112A1 (en) 2011-04-08 2012-10-11 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Ubiquitin fusions for improving the efficacy of cytosolic acting targeted toxins
EP2694640B1 (en) 2011-04-08 2017-10-18 Baylor College Of Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
US9512194B2 (en) 2012-01-27 2016-12-06 The Board Of Trustees Of The Leland Stanford Junior University Modified IL-13 polypeptides
CN105722860A (zh) 2013-09-24 2016-06-29 梅迪塞纳医疗股份有限公司 白介素-2融合蛋白及其应用
JP6936934B2 (ja) 2013-09-24 2021-09-22 メディシナ セラピューティクス インコーポレイテッド インターロイキン−４受容体結合融合タンパク質及びその使用
EP3068797B1 (en) 2013-11-11 2020-01-08 Wake Forest University Health Sciences Constructs for multi-valent targeting of tumors
ES2959480T3 (es) 2014-02-07 2024-02-26 Univ Mcmaster Acoplador de células T - antígeno trifuncional y métodos y usos del mismo
WO2016040441A1 (en) 2014-09-09 2016-03-17 Unum Therapeutics Chimeric receptors and uses thereof in immune therapy
ES2738705T3 (es) 2014-09-19 2020-01-24 Hope City Linfocitos T de receptor de antígeno quimérico coestimulante que se dirigen a IL13R 2
EP3227317A4 (en) 2014-12-02 2018-04-25 Roger Williams Hospital Methods and compositons for treating cancer
JP6993699B2 (ja) 2016-01-11 2022-02-03 ウニヴェルズィテート・ツューリヒ ヒトインターロイキン－２に対する免疫刺激性ヒト化モノクローナル抗体及びその融合タンパク質
US20200095301A1 (en) 2016-12-14 2020-03-26 The Board Of Trustees Of The Leland Stanford Junior University Il-13 superkine: immune cell targeting constructs and methods of use thereof
WO2019051204A1 (en) 2017-09-08 2019-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services SYNERGISTIC COMBINATION OF IL4, INTERFERON GAMMA AND INTERFERON ALPHA RECEPTOR AGENTS FOR USE IN THE TREATMENT OF OVARIAN CANCER
CA3078434A1 (en) 2017-10-10 2019-04-18 Medicenna Therapeutics, Inc. Il-4-fusion formulations for treatment of central nervous system (cns) tumors
WO2020160639A1 (en) 2019-02-07 2020-08-13 Medicenna Therapeutics, Inc. Il-4r as a biomarker in cancer
EP4172216A4 (en) 2020-06-24 2024-12-04 Medicenna Therapeutics, Inc. BIFUNCTIONAL SUPERKINE AND USES THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335426B1 (en) * 1996-06-14 2002-01-01 Bayer Corporation T-cell selective interleukin-4 agonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BATES D. L. ET AL.: "3QB7：Interleukin-4 mutant RGA bound to cytokine receptor common gamma", 《RCSB PDB》 *
CREUSOT ET AL.: "Engineering cell-type selective immune responses using mechanism-based designer IL-4 cytokines", 《THE JOURNAL OF IMMUNOLOGY》, vol. 186, 31 December 2011 (2011-12-31) *
SCHNARE ET AL.: "Specific Antagonism of Type I IL-4 Receptor with a Mutated Form of Murine IL-4", 《THE JOURNAL OF IMMUNOLOGY》, vol. 161, 31 December 1998 (1998-12-31) *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110582293A (zh) * 2017-03-31 2019-12-17 小利兰·斯坦福大学托管委员会 合成因子组合物及使用方法
US12540188B2 (en) 2020-08-05 2026-02-03 Synthekine, Inc. IL10Rα/IL2Rγ synthetic cytokines

Also Published As

Publication number Publication date
WO2014074186A3 (en) 2014-06-19
WO2014074186A2 (en) 2014-05-15
US20160244499A1 (en) 2016-08-25
EP2882449B1 (en) 2019-05-15
US9738696B2 (en) 2017-08-22
IN2015KN00329A (cg-RX-API-DMAC7.html) 2015-07-10
EP2882449A4 (en) 2016-03-09
US20180016316A1 (en) 2018-01-18
JP6445434B2 (ja) 2018-12-26
JP2018161143A (ja) 2018-10-18
EP2882449A2 (en) 2015-06-17
US10738096B2 (en) 2020-08-11
US12187771B2 (en) 2025-01-07
JP2015525574A (ja) 2015-09-07
CN110615835A (zh) 2019-12-27
US20210188932A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
US12187771B2 (en) Method of producing Th9 T-cells
JP7729570B2 (ja) インターロイキン－２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
Bernstein et al. Engineering the IL‐4/IL‐13 axis for targeted immune modulation
JP6441867B2 (ja) インターロイキン２のスーパーアゴニストおよびアンタゴニスト
CN110392695B (zh) 针对cd127的抗体和多肽
WO2006023791A2 (en) Methods and compositions for treating allergic inflammation
CN110974958B (zh) 一种抗pd-l1单克隆抗体的注射制剂
US20110311475A1 (en) Means and method for the treatment of antibody deficiency diseases based on il-21 and il-21 variants
Shilovskiy et al. Role and molecular mechanisms of alternative splicing of Th2-cytokines IL-4 and IL-5 in atopic bronchial asthma
CN112843222A (zh) Ankrd22蛋白在制备治疗或延缓自身免疫性疾病的产品中的应用
CN114380919A (zh) 经修饰的il-2分子及其用途
CN103382220A (zh) 具有抗感染、抗肿瘤活性的细胞因子fam19a4及其应用
TW202330631A (zh) ＳＩＲＰａ突變體及其應用
WO2022036196A2 (en) Use of vista agonist for treatment/prevention of cytokine storm or crs or sepsis and/or acute or chronic respiratory distress syndrome (rds)
Rosenberg et al. Characterization of Lamprey IL-17 Family
Mori et al. Eosinophil lineage-committed progenitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20150513

RJ01 Rejection of invention patent application after publication